Marina Biotech, Inc. (OTCMKTS:MRNA) Files An 8-K Other Events

Item 8.01 Other Events.

On January 3, 2017, Marina Biotech Inc. (the Company) issued a
press release announcing that the Company was granted a patent
for Bacteria Mediated Gene Silencing (EP 08768475.9, European
Patent 2173875) claims by the European Patent Office. The granted
claims relate to the Companys tkRNAi technology being utilized in
its CEQ508 program that is being developed to treat familial
adenomatous polyposis (FAP).

A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

Exhibit 99.1: Press Release of Marina Biotech Inc. date January
3, 2017.

About Marina Biotech, Inc. (OTCMKTS:MRNA)

Marina Biotech, Inc. is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. The Company’s pipeline includes CEQ508, a product in clinical development for the treatment of Familial Adenomatous Polyposis (FAP), and preclinical programs for the treatment of type 1 myotonic dystrophy (DM1) and Duchenne muscular dystrophy (DMD). It creates a range of therapeutics targeting coding and non-coding ribonucleic acid (RNA) through several mechanisms of action, such as RNA interference (RNAi), messenger RNA translational inhibition, exon skipping, microRNA (miRNA) replacement, miRNA inhibition and steric blocking in order to modulate gene expression either up or down depending on the specific mechanism of action. It has two liposomal-based delivery platforms: SMARTICLES, and the platform, which utilizes amino-based liposomal delivery technology and incorporates a molecule, Di-Alkylated Amino Acid (DiLA2).

Marina Biotech, Inc. (OTCMKTS:MRNA) Recent Trading Information

Marina Biotech, Inc. (OTCMKTS:MRNA) closed its last trading session 00.000 at 0.169 with 46,468 shares trading hands.